KYV-101 is under clinical development by Kyverna Therapeutics and currently in Phase I for Lupus Nephritis. According to GlobalData, Phase I drugs for Lupus Nephritis have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KYV-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KYV-101 is under development for the treatment of refractory myasthenia gravis, relapsed or refractory lupus nephritis and diffuse cutaneous systemic sclerosis (scleroderma), multiple sclerosis, idiopathic necrotizing myopathy (INM) consisting of dermatomyositis (DM), necrotizing myopathy, anti-HMGCoA-associated myopathy, and polymyositis (PM), diffuse cutaneous systemic sclerosis (dcSSc), systemic lupus erythematosus (SLE) with nephritis, and ANCA-associated vasculitis (AAV). It targets B cell antigen CD-19. It is based an autologous CAR-T cell therapy. The drug candidate is administered through intravenous route.
Kyverna Therapeutics overview
Kyverna Therapeutics (Kyverna) is a cell therapy company that is into advancing treatment options for addressing the unmet medical needs for inflammatory and autoimmune diseases. The company utilizes synReg-T cell (synthetic regulatory T cells) platform technology which facilitates engineering and genetic reprogramming of synReg-T cells to suppress autoimmune diseases and synNotch CAR-T platform, a synthetic gene expression system that enables the development of synNotch CAR-T cells (chimeric antigen receptor T cells) against autoimmune diseases. It is investigating engineered T cell therapies to treat lupus nephritis, systemic sclerosis and inflammatory bowel disease (IBD) through SmarTcell, a genetic engineering toolbox. The company’s key funding partners include Vida Ventures, Westlake Village BioPartners, and Gilead Sciences Inc. Kyverna is headquartered in Emeryville, California, the US.
For a complete picture of KYV-101’s drug-specific PTSR and LoA scores, buy the report here.